A Promising New Treatment For Dementia Could Help Patients Manage Side Effects Better

Mahatma Gandhi said that “the true measure of any society can be found in how it treats its most vulnerable members.” As life expectancies continue to increase, there is an ever-greater need to tackle health problems that afflict the elderly, the fastest-growing segment of the vulnerable.

Neurological disorders — often resulting from debilitation of the central nervous system (CNS) — affect 1 in 6 people globally. In the U.S., 6.5 million people are affected by Alzheimer’s, a common CNS disease. This number will only increase as the group most at risk from Alzheimer’s disease — people older than 65 — continues to grow. 

Kurve Therapeutics Inc. is looking to bring real treatments for those suffering from Alzheimer’s and other neurological conditions. It is now open to investment from retail investors through a Regulation A+ offering. 

Investing In The Future Of Brain-Healthy Treatment

Several diseases can affect the brain as the body ages. Dementia is a common disease where brain deterioration causes memory loss and cognitive impairment. While slight memory impairment is a common consequence of aging, contrary to popular belief, dementia itself is not a natural part of aging. Alzheimer’s is the most common form of dementia, though neurodegeneration accompanies several central nervous system diseases, including Parkinson’s (affecting 8.5 million globally) and multiple sclerosis (2.5 million globally).

The medical landscape is struggling to find solutions that effectively treat Alzheimer’s. Despite expensive investments in drug trials and development, most drugs on the market are not disease-modifying treatments (DMT). Instead of modifying the disease, they provide short-term symptomatic treatment. Inability to bypass the blood-to-brain barrier (BBB) and the invasive, deleterious side effects common to most drugs on the market make such treatments unappealing. Furthermore, the development of disease-modifying treatments has been prevented by the inability to bypass the blood-to-brain barrier (BBB). 

Kurve is looking to change the scene. It claims that its ViaNase Intelligent Delivery treatment — featured by peer-reviewed journals like John Hopkins Medicine and Medscape — can bring actual DMT solutions with minimal side effects to those afflicted with Alzheimer’s and other neurodegenerative diseases. The journals report statistically-significant improvements (compared with placebo) in Alzheimer’s (five clinical trials), Parkinson’s (one clinical trial) and other CNS disorders.

ViaNase involves a novel nose-to-brain delivery that allows the medication to bypass the BBB via olfactory nerves. Using Kurve’s patented controlled-particle dispersion (CPD) technology allows the ViaNase treatment to be administered with greater dosage control. This manages side effects, as the medicine is treating only the targeted area and allows greater precision for medication dosage. Through its innovative nasal treatment, Kurve is cutting a new path into the flourishing nasal-delivery technology market.

Retail investors can now buy shares of Kurve. Its Regulation A+ offering is for $50 million, at $5.80 a share with a minimum investment of $580. Its primary target markets for the drug are Alzheimer’s, Parkinson’s and diabetic cognitive decline. However, it hopes to expand via its secondary market to treat a wide variety of CNS diseases. 

To learn more about Kurve Therapeutics, click here.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by Vlad Sargu on Unsplash